Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04582136Phase 3Active Not Recruiting

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

Role: collaborator

NCT04892212Phase 2Unknown

Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

Role: collaborator

NCT01451749Phase 3Completed

Efficacy and Safety Study of Shenwu Capsule

Role: lead

All 3 trials loaded